Intended for Canadian Healthcare Professionals Only

Micro-Debridement with Collagenase SANTYL® Ointment

Inflammation can stall wound healing1

The presence of debris stimulates an influx of inflammatory cells, which can prolong the chronic wound cycle1

cycle on inflammation

Chronic wounds show signs of inflammation1

Even after macroscopic (sharp or surgical) debridement, inflammatory processes continue to generate microscopic cellular debris, which prolongs the healing process8-15

Chronic wounds show signs of inflammation

  • Histology shows coagulative tissue necrosis bordered by granulation tissue

Continuous, active micro-debridement

SANTYL® Ointment can help wounds progress from the inflammatory to the proliferative phase of healing

  • Recent professional guidelines recommend continuous debridement to prepare the wound bed for healing16-18

  • The continuous, active removal of necrotic materials with SANTYL® Ointment can help to prevent reaccumulation of the harmful debris that can prolong the healing process, thus allowing granulation to proceed and epithelialization to occur

Images courtesy of Robert Wiemer, DPM FACFAS; Mercy Health Center, Philadelphia, PA

Clinical Materials & Resources

Occasional slight transient erythema has been noted in surrounding tissue when applied outside the wound. One case of systemic hypersensitivity has been reported after 1 year of treatment with collagenase and cortisone.
Use of Collagenase SANTYL® Ointment should be terminated when debridement is complete and granulation tissue is well established.
See complete prescribing information for more details.

References: 1. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341:738-746. 2. Goldman R. Growth factors and chronic wound healing: past, present, and future. Adv Skin Wound Care. 2004;17:24-35. 3. Schulz GS, Mast BA. Molecular analysis of the environments of healing and chronic wounds: cytokines, proteases, and growth factors. Wounds. 1998;10(suppl F):1F-9F. 4. Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Inv Dermatol. 2007;127:514-525. 5. Lobmann R, Schulz G, Lehnert H. Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes Care. 2005;28:461-471. 6. Yager DR, Nwomeh BC. The proteolytic environment of chronic wounds. Wound Rep Reg. 1999;7:433-441. 7. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Rep Reg. 1996;4:411-420. 8. Ayello EA, Cuddigan JE. Debridement: Controlling the necrotic/cellular burden. Adv Skin Wound Care. 2004;17:66-75. 9. Enoch S, Harding K. Wound bed preparation: the science behind the removal of barriers to healing. Wounds. 2003;15:213-229. 10. Steed DL. Debridement. Am J Surg. 1994;187:71S-74S. 11. Fowler E, van Rijswijk L. Using wound debridement to help achieve the goals of care. Ostomy Wound Manage. 1995;41:23S-35S. 12. Schultz G, Sibbald G, Falanga et al. Wound bed preparation: a systemic approach to wound management. Wound Repair Regen. 2003;11:S1-S28. 13. Sibbald RG. Preparing the wound bed-debridement bacterial balance and moisture balance. Ostomy Wound Manage. 2000:46; 14-35. 14. Hellgren L, Vincent J. Debridement: An essential step in wound healing. In: Westerhoff W, ed. Leg Ulcers: Diagnosis and Treatment. Amsterdam, Netherlands: Elsevier Science; 1993:305. 15. Brem H, Lyder C. Protocol for the successful treatment of pressure ulcers. Am J Surg. 2004;188:9S-17S. 16. Robson MC, Cooper DM, Aslam R, et al. Guidelines for the treatment of venous ulcers. Wound Rep Reg. 2006;14:649-662. 17. Whitney J, Phillips L, Aslam R, et al. Guidelines for the treatment of pressure ulcers. Wound Repair Reg. 2006;14:663-679. 18. Steed DL, Attinger C, Colaizzi T, et al. Guidelines for the treatment of diabetic ulcers. Wound Repair Reg. 2006;14:680-692.
Mechanism of Action Video

moa video
About SANTYL® Ointment

Active Micro-Debridement
Active Micro-Debridement
learn more link
Application Protocol for
SANTYL® Ointment

learn more link
SANTYL® is a registered trademark of Healthpoint Biotherapeutics. Healthpoint Biotherapeutics and design is a registered trademark of Healthpoint Biotherapeutics.
© 2010 Healthpoint Canada ULC. All rights reserved.
The information on this site is intended for customers, patients, and healthcare professionals in Canada only. All information, including the Prescribing Information for Collagenase SANTYL® Ointment, abides by the laws, regulatory requirements, and medical practices for Canada only and may not be appropriate for use outside of Canada.